The inflammatory tumor microenvironment (TME) is a complex network of cancer, immune, and stromal cells interacting through cytokines and growth factors to drive tumor growth, angiogenesis, and immune ...

A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...

T cell senescence occurs in the TME, affecting cancer prognosis and immunotherapy efficacy. The TME induces T cell senescence through multiple pathways, including persistent stimulation by ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...

Large BIDMC-led study maps immune cells in myeloma tumors, improving risk prediction beyond genetics and helping identify ...

Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, it is worth highlighting ...

The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...

As people age, their immune function gradually declines, coinciding with increased cancer rates. However, the precise reasons behind age-related dysfunction of CD8+ T cells in cancer remain unclear.

Cancer immunotherapy has already transformed treatment for some patients, yet too often the body’s defenders stall out before ...